UK markets close in 22 minutes

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4118-0.0008 (-0.19%)
As of 10:52AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.4126
Open0.4165
Bid0.2889 x 200
Ask0.5263 x 200
Day's range0.4039 - 0.4190
52-week range0.2570 - 3.2800
Volume65,453
Avg. volume331,820
Market cap13.723M
Beta (5Y monthly)3.56
PE ratio (TTM)0.11
EPS (TTM)3.8300
Earnings date13 Jun 2024 - 14 Jun 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est760.00
  • PR Newswire

    RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent notice of allowance for opaganib[4] in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response, providing protection for opaganib's potential use with a range of approved and in-development immune checkpoint inhibitors (ICIs) across a growing range of indications through 2040. The patent wi

  • The Telegraph

    Pensioners win £9,000 back in 16-year council tax battle

    Residents in a retirement village will have their council tax cut after winning a 16-year-long battle over incorrect bills.

  • PR Newswire

    RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

    RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).